摘要
目的观察罗格列酮治疗非酒精性脂肪性肝炎(NASH)的疗效。方法将78例NASH患者随机分为治疗组和对照组,各39例。在常规治疗基础上,治疗组加用罗格列酮4 mg口服,2次/d;对照组加用能量合剂静脉滴注,1次/d。治疗12周后比较两组患者的疗效、肝功能及血清瘦素水平。结果治疗组显效32例,有效5例,无效2例;对照组显效24例,有效7例,无效8例,两组疗效间差异有统计学意义(u=2.14,P<0.05)。治疗组和对照组患者治疗后血清丙氨酸氨基转移酶〔(48±19)U/L和(67±19)U/L〕、天冬氨酸氨基转移酶〔(37±8)U/L和(46±17)U/L〕、谷氨酰转肽酶〔(61±10)U/L和(72±14)U/L〕水平间差异均有统计学意义(P<0.01)。治疗后治疗组男女血清瘦素水平〔(11±9)ng/m l和(26±15)ng/m〕l与治疗前〔(16±7)ng/m l和(33±17)ng/m〕l比较,差异均无统计学意义(t值分别为1.73、1.37,P>0.05)。两组患者治疗中均未发生不良反应。结论罗格列酮治疗NASH安全、有效,能显著改善肝功能。
Objective To observe the effect of Rosiglitazone in treatment of patients with non-alcoholic steatohepatitis(NASH).Methods Totally 78 NASH patients were randomly divided as trial group(n=39) and control group(n=39).All the patients were given conventional treatment,and the patients in the trial group were treated with oral Rosiglitazone,4 mg twice a day,while those in the control group with intravenous drop of energy mixture,once a day,for 12 weeks.Then the effects,liver functions and leptin between the two groups were compared.Results In the trial group there were 32 cases with a remarkable effect,5 case with effect and 2 cases with no effect,as compared with those of 24,7 and 8 respectively in the control group,the differences were significant(u=2.14,P<0.05).After treatment,the differences in levels of serum ALT [(48±19)U/L and(67±19)U/L],AST [(37±8)U/L and(46±17)U/L] and GGT [(61±10)U/L and(72±14) U/L] were statistically significant(P<0.01).The levels of leptin for man and woman in the trial group were(11±9) ng/ml and(26±15)ng/ml after treatment,which showed a significant difference from those [(16±7)ng/ml and(33±17)ng/ml] before treatment(t=1.73,1.37;P>0.05).No untoward effect was found in the patients of both groups.Conclusion Rosiglitazone is safety and effective in treating NASH,and it can remarkably improve liver function.
出处
《中国全科医学》
CAS
CSCD
北大核心
2009年第11期949-951,共3页
Chinese General Practice
关键词
脂肪肝
非酒精性
罗格列酮
治疗结果
Fatty liver,non-alcoholic
Rosiglitazone
Treatment outcome
